Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy

Leukemia

Volumn 12, Issue 1, 1998, Pages 13-24

  Engelhardt, M ^a,c   Ozkaynak, M F ^b   Drullinsky, P ^a   Sandoval, C ^b   Tugal, O ^b   Jayabose, S ^b   Moore, M A S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Solid and liquid tumors; Telomerase; Telomeres

Indexed keywords

CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; IDARUBICIN; TELOMERASE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GRANULOCYTE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; MALE; MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; RESTRICTION FRAGMENT; SCHOOL CHILD; SOLID TUMOR; TELOMERE;

EID: 0031962410     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400889     Document Type: Article

References (64)

1. Sawyers CL, Denny CT, Witte ON. Leukemia and the disruption of normal hematopoiesis. Cell 1991; 64: 337-350.
2. George SL, Aur RJA, Maurer AM, Simone JV. A reappraisal of the results of stopping therapy in childhood leukemia. New Engt J Med 1979; 300: 269-273.
3. Blackburn EH. Structure and function of telomeres. Nature (Lond) 1991; 266: 569-573.
4. Harley CB, Kim NW, Prowse KR et al. Telomerase, cell immortality, and cancer: Cold Spring Harbor Symp. Quant Biol 1994; 59: 307-315.
5. Landsdorp PM. Telomere length and proliferation potential of hematopoietic stem cells. J Cell Sci 1995; 108: 1-6.
6. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
7. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 1995; 92: 9082-9086.
8. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995; 85: 2315-2320.
9. Engelhardt M, Kumar R, Albanell J, Pettengell R, Han W, Moore MAS. Telomerase regulation, cell cycle and telomere stability in primitive hematopoietic cells. Blood 1997; 90: 182-193.
10. Igarashi H, Sakaguchi N. Telomerase activity is induced in human peripheral B lymphocytes by the stimulation to antigen receptor. Blood 1997; 89: 1299-1307.
11. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Landsdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 1994; 91: 9857-9860.
12. Counter CM, Avilion AA, LeFeuvre CE et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992; 11: 1921-1929.
13. Allsopp RC, Vaziri H, Patterson C et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 1992; 89: 10114-10118.
14. Albanell J, Man W, Mellado B et al. Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines. Cancer Res 1996; 56: 1503-1508.
15. Hiyama E, Hiyama K, Yokoyama T Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med 1995; 1: 249-255.
16. Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 1994; 91: 2900-2904.
17. Hiyama E, Yokoyama T, Tatsumoto N et al. Telomerase activity in gastric cancer. Cancer Res 1995; 55: 3258-3262.
18. Hiyama K, Hiyama E, Ishioka S et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995; 87: 895-902.
19. Mehle C, Ljungberg B, Roos C. Telomere shortening in renal cell carcinoma. Cancer Res 1994; 54: 236-241.
20. Mehle C, Piatyszek MA, Ljungberg B, Shay JW, Roos G. Telomerase activity in human renal cell carcinoma. Oncogene 1996; 13: 161-166.
21. Gupta J, Han L-P, Wang P, Gallie BL, Bacchetti S. Development of retinoblastoma in the absence of telomerase activity. J Natl Cancer Inst 1996; 88: 1152-1157.
22. Langford LA, Piatyszek MA, Xu R, Schold Jr SC, Shay JW. Telomerase activity in human brain tumors. Lancet 1995; 346: 1267-1268.
23. Zhang W, Piatyszek MA, Kobayashi T et al. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res 1996; 2: 799-803.
24. Shay JW, Werbin H, Wright WE. Telomeres and telomerase in human leukemias. Leukemia 1996; 10: 1255-1261.
25. Hastie ND, Demster M, Dunlop MG, Thomson AM, Green DK, Alshire RC. Telomere reduction in human colorectal carcinoma and with aging. Nature 1990; 346: 866-868.
26. Tahara H, Kuniyasu H, Yokozaki H et al. Telomerase activity in preneoplastic and neoplastic gastric colorectal lesions. Clin Cancer Res 1995; 1: 1245-1251.
27. Li ZH, Salovaara R, Aaltonen LA, Shibata D. Telomerase activity is commonly detected in hereditary nonpolyposis colorectal cancers. Am J Pathol 1996; 148: 1075-1079.
28. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996; 56: 218-222.
29. Brousset P, Saati TA, Chaouche N et al. Telomerase activity in reactive and neoplastic lymphoid tissues: infrequent detection of activity in Hodgkin's disease. Blood 1997; 89: 26-31.
30. Eeng J, Funk WD, Wang S-S et al. The RNA component of human telomerase. Science 1995; 269: 1236-1241.
31. Harrington L, McPhail T, Mar V et al. A mammalian telomerase-associated protein. Science 1997; 275: 973-977.
32. Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 1997; 276: 561-567.
33. Marcand S, Gilson E, Shore D. A protein-counting mechanism for telomere length regulation in yeast. Science 1997; 275: 986-990.
34. Cooper JP, Nimmo ER, Allshire RC, Cech TR. Regulation of telomere length and function by a myb-domain protein in fission yeast. Nature 1997; 385: 744-747.
35. Chong L, Van Steensel B, Broccoli D et al. A human telomeric protein. Science 1995; 270: 1663-1667.
36. Van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997; 385: 740-743.
37. Buhrer C, Hartmann R, Fengler R et al. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group. J Clin Oncol 1996; 14: 2812-2817.
38. Weite K, Reiter A, Mempel K et al. A randomized phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group. Blood 1996; 87: 3143-3150.
39. Vormoor J, Boos J, Stahnke K, Jurgens H, Ritter J, Creutzig U. Therapy of childhood acute myelogenous leukemias. Ann Hematol 1996; 73: 11-24.
40. Steinherz PC, Gaynon PS, Breneman JC et al. Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance of early marrow response: report from the children's cancer group. J Clin Oncol 1996; 14: 389-398.
41. Baez F, Ocampo E, Conter V et al. Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radio-therapy in Nicaragua. Ann Oncol 1997; 8: 247-250.
42. Hudson MM. Treatment of childhood Hodgkin's disease with chemotherapy alone. Ann Oncol 1997; 8: 215-216.
43. Piatyszek AM, Kim NW, Weinrich SL et al. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol. (TRAP). Meth Cell Sci 1995; 17: 1-15.
44. Khouri I, Sanchez FG, Deisseroth A. Acute leukemias. In: DeVita VT, Hellmann S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. Lippincott-Raven: New York, 1997, pp 2285-2292.
45. Marks DI, Kurz BW, Link MP et al. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol 1997; 15: 1158-1162.
46. Ohyashiki JH, Ohyashiki K, Iwama H, Hayashi S, Toyama K, Shay JW. Clinical implications of telomerase activity levels in acute leukemia. Clin Cancer Res 1997; 3: 619-625.
47. Iwama H, Ohyashiki K, Ohyashiki JH et al. The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia. Cancer 1977; 79: 1552-1560.
48. Adamson DJA, King DJ, Haites NE. Significant telomere shortening in childhood leukemia. Cancer Genet Cytogenet 1992; 61: 204-206.
49. Ohyashiki K, Ohyashiki JH, Iwama H, Hayashi S, Shay JW, Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia 1997; 11: 190-194.
50. Holt SE, Shay JW, Wright WE. Refining the telomere-telomerase hypothesis of aging and cancer. Nature Bio 1996; 14: 836-839.
51. Engelhardt M, Albanell J, Drullinsky P et al. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon and sarcoma. Clin Cancer Res 1997; 3: 1849-1857.
52. Engelhardt M, Drullinsky P, Guillem J, Moore MAS. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res 1997; 3: 1931-1941.
53. Hiyama K, Hirai Y, Kyoizumi S et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995; 155: 3711-3715.
54. Norrback KF, Dahlenborg K, Carlsson R, Roos G. Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas. Blood 1996; 88: 222-229.
55. Brousset P, Saati TA, Chaouche N et al. Telomerase activity in reactive and neoplastic lymphoid tissues: infrequent detection of activity in Hodgkin's disease. Blood 1997; 89: 26-31.
56. Harley CB, Futcher AB, Greider CW. Telomeres shortening during ageing of human fibroblasts. Nature (Lond) 1990; 345: 458-460.
57. Allsopp RC, Chang E, Kashefi-Aazam M et al. Telomere shortening is associated with cell division in vitro and in vivo. Exp Cell Res 1995; 220: 194-200.
58. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1996; 14: 4240-4248.
59. Hiyama E, Yokoyama T, Hiyama K et al. Alteration of telomeric repeat length in adult and childhood solid neoplasias. Int J Oncol 1995; 6: 13-16.
60. Ohyashiki K, Ohyashiki JH, Fujimura T et al. Telomere shortening in leukemic cells is related to their genetic alterations but not replicative capability. Cancer Cenet Cytogenet 1994; 78: 64-67.
61. Podesta M, Piaggio G, Frassoni F et al. Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 1011-1017.
62. Yasumoto S, Kunimura C, Kikuchi K et al. Telomerase activity in normal human epithelial cells. Oncogene 1996; 13: 433-439.
63. Harle-Bachor C, Boukamp P. Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci USA 1996; 93: 6476-6481.
64. Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 1997; 25: 2595-2597.